Mechanisms of p53-induced apoptosis: In search of genes which are regulated during p53-mediated cell death

Toxicology Letters

Volumn 102-103, Issue , 1998, Pages 491-496

  Choisy Rossi, Caroline ^a   Reisdorf, Philippe ^a   Yonish Rouach, Elisheva ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Apoptosis; Differential display; Growth arrest; p53; Sequence specific transcriptional activation

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; CELL CYCLE; CELL LINE; CONFERENCE PAPER; DNA REPAIR; GENETIC TRANSCRIPTION; MUTATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENES; HUMANS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032439403     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00238-0     Document Type: Conference Paper

References (39)

1. Bargonetti, J., Manfredi, J.J., Chen, X., Marshak, D.R., Prives, C.A., 1993. Proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7, 2565-2574.
2. Bayle, J.H., Elenbaas, B., Levine, A.J., 1995. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA 92, 5729-5733.
3. Bourdon, J.C., Deguin-Chambon, V., Lelong, J.C., Dessen, P., May, P., Debuire, B., May, E., 1997. Further characterisation of the p53 responsive element - identification of new candidate genes for trans-activation by p53. Oncogene 14, 85-94.
4. Chang, J., Kim, D.H., Lee, S.W., Choi, K.Y., Sung, Y.C., 1995. Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein. Biol. Chem. 270, 25014-25019.
5. Cho, Y., Gorina, S., Jeffrey, P.D., Pavletich, N.P., 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355.
6. Choisy-Rossi, C., Reisdorf, P., Yonish-Rouach, E., 1998. The p53 tumor suppressor gene: structure, function and mechanism of action. In: Kumar, S. (Ed.), Results and Problems in Cancer Research, vol. 23. Springer-Verlag, Heidelberg, in press.
7. Donehower, L.A., Bradley, A., 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155, 181-205.
8. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Jr., Butel, J.S., Bradley, A., 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
9. El-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W., Vogelstein, B., 1992. Definition of a consensus binding site for p53. Nature Genet. 1, 45-49.
10. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., Prives, C., 1992. Wild-type p53 activates transcription in vitro. Nature 358, 83-86.
11. Fields, S., Jang, S.K., 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249, 1046-1049.
12. Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E., Shay, J.W., 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866-2871.
13. Halazonetis, T.D., Kandil, A.N., 1993. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J. 12, 1021-1028.
14. Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., Harris, C.C., 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucl. Acids Res. 22, 3551-3555.
15. Hupp, T.R., Meek, D.W., Midgley, C.A., Lane, D.P., 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucl. Acids Res. 21, 3167-3174.
16. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., Craig, R.W., 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
17. Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., Vogelstein, B., 1991. Identification of p53 as a sequence-specific DNA binding protein. Science 252, 1708-1711.
18. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V., Kastan, M.B., 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491-7495.
19. Lane, D.P., 1992. p53, guardian of the genome. Nature 358, 15-16.
20. Lee, S., Elenbaas, B., Levine, A., Griffith, J., 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81, 1013-1020.
21. Levine, A.J., 1997. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
22. Liang, P., Pardee, A.B., 1992. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967-971.
23. Lin, J., Chen, J., Elenbaas, B., Levine, A.J., 1994. Several hydrophobic amino acids in the p53-amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246.
24. Liu, X., Miller, C.W., Koeffler, P.H., Berk, A.J., 1993. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13, 3291-3300.
25. Meek, D.W., Campbell, L.E., Jardine, L.J., Knippschild, U., McKendrick, L., Milne, D.M., 1997. Multi-site phosphorylation of p53 by protein kinases inducible by p53 and DNA damage. Biochem. Soc. Trans. 25, 416-419.
26. Milczarek, G.J., Martinez, J., Bowden, G.T., 1997. p53 Phosphorylation: biochemical and functional consequences. Life Sci. 60, 1-11.
27. Pavletich, N.P., Chambers, K.A., Pabo, C.O., 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7, 2556-2564.
28. Pietenpol, J.A., Tokino, T., Thiagalingam, S., El-Deiry, W.S., Kinzler, K.W., Vogelstein, B., 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91, 1998-2002.
29. Raycroft, L., Wu, H., Lozano, G., 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249, 1049-1051.
30. Shaulian, E., Zauberman, A., Milner, J., Davies, E.A., Oren, M., 1993. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J. 12, 2789-2797.
31. Slingerland, J.M., Jenkins, J.R., Benchimol, S., 1993. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J. 12, 1029-1037.
32. Soussi, T., Caron de Fromentel, C., May, P., 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5, 945-952.
33. Stürzbecher, H.-W., Brain, R., Addison, C., Rudge, K., Remm, M., Grimaldi, M., Keenan, E., Jenkins, J.R., 1992. A C-terminal α-helix plus basic region is the major structural determinant of p53 tetramerization. Oncogene 7, 1513-1523.
34. Tarunina, M., Jenkins, J.R., 1993. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene 8, 3165-3173.
35. Unger, T., Nau, M.M., Segal, S., Minna, J.D., 1992. p53: a trans-dominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11, 1383-1390.
36. Wang, Y., Reed, M., Wang, P., Stenger, J.E., Mayr, G., Anderson, M.E., Schweded, J.F., Tegtmeyer, P., 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7, 2575-2586.
37. Wu, Y., Liu, Y., Lee, L., Miner, Z., Kulesz-Martin, M., 1994. Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J. 13, 4823-4830.
38. Yonish-Rouach, E., 1997. A question of life or death: the p53 tumor suppressor gene. Pathol. Biol. 45, 824-832.
39. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., Oren, M., 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347.